MTPC $1.1 billion acquisition of NeuroDerm

18/10/2017

Private acquisition

Value:

$ 1.1 billion

Status:

Announced

Date:

18/10/2017

Overview:

Mitsubishi Tanabe Pharmaceutical Corporation (MTPC), a Japanese pharmaceuticals company, has acquired NeuroDerm for $1.1 billion.
MTPC paid a price of $39 per share in what is the largest acquisition of a healthcare company in Israel.
Previously—in November 2014—NeuroDerm undertook an IPO setting a price of $10 per share.

Katrin Kostadinova - Data analyst

Jurisdictions:

Japan
Israel

Deal type:

Private acquisition

Practice area:

M&A

Governing law:

Israel

Industry sector:

Pharmaceuticals and life sciences

Firms:

Meitar | Law Offices

Party: NeuroDerm (Target)

White & Case

Party: NeuroDerm (Target)

Lawyers: Colin Diamond, Gregory Pryor

Related deals